The Incest of ASX Biopharma

It’s pretty hard to beat the Brits when it comes to situational comedy. As a dual-Australian/Canadian national educated in the UK, I suppose I have an intrinsic affinity for that dry, offhand style of humour. A few years ago, I stumbled across a brilliant comedy skit that visually captures precisely the fundamental reason why ASX biopharma is…

Alchemia has a VAST problem

It was only two years ago that Alchemia (ASX : ACL) informed us, with great fanfare and celebration, of the collaboration with AstraZeneca involving the VAST program. It was a pretty exciting story, especially for an early-stage platform technology. R&D cost offsets, potential milestones/royalties. Big potential, heady stuff. Two years on, we have seen the company’s fortunes…

Neuren – A Can of Worms

Firstly, I would like to start this post by promoting another blog – specifically Trail to a Texas Trial. For anyone who is passionate about Rett Syndrome, it is powerful and emotional reading. I received a rather scathing retort from Melinda Lancaster, the owner of the site and the mother of a girl named Katelin who is…

Circadian – A Nice Little Rhythm

Ever since I started this blog, I have been asked by many whether there are any ASX life sciences / healthcare companies that I actually like. I think I have always been consistent in the viewpoint that I genuinely believe in the potential of Australian life sciences. If I didn’t, this would be a fairly…